New research reveals fundamental roles for astrocytes and microglia in shaping neural circuits.
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.
The Internet is poised to play a growing role in recruiting for Alzheimer’s clinical trials.
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
With several microRNAs being overly active in ALS, an antisense therapy to one slows the disease in mice, apparently by reducing neuroinflammation.
New strategies may help find and retain participants for Alzheimer’s trials.
Researchers propose four stages of TDP-43 pathology based on the spread of the protein through the brain.
Meet ADCS-PACC, C3: Composites that measure subtle changes in cognition appear reliable, clearing the way for their use in clinical trials of people with presymptomatic AD.
Researchers find an actin-binding protein in stress granules, linking the cytoskeleton and RNA sequestration in the pathology of amyotrophic lateral sclerosis.
The latest news on C9ORF72 includes a genetic modifier, various animal models, and a potential treatment to untangle stable, guanine-based structures formed by expanded repeats.
Is transfer of tau from one neuron to the next a normal activity, hijacked by pathogenic protein in the case of tauopathies?
AD but no Amyloidβ? Researchers at AAIC 2013 theorized on the pathology underlying this form of dementia.
Studies reported at AAIC demonstrate that biomarkers help predict who will develop cognitive impairment and dementia.
Hunting for rare mutations that cause dementia, researchers have spotted, but not yet snagged, some tantalizing candidates.
Tau ligands for PET scans were among the hot topics at the Alzheimer’s Association International Conference in Boston.